Rebus Holdings Inc (RBSH)

[powerbattles]

INSPYR THERAPEUTICS INC (NSPX) FUNDAMENTALS & COMPANY PROFILE

<><><><><>BREAKING NEWS!<><><><><><>

Inspyr Therapeutics: Can This High Potential Cancer Killing Biotech Repurpose Drugs to Help Fight COVID-19?
https://www.marketwatch.com/press-release/inspyr-therapeutics-can-this-high-potential-cancer-killing-biotech-repurpose-drugs-to-help-fight-covid-19-2020-03-24

"Inspyr merged with Lewis and Clark Pharmaceuticals several years ago and since then has developed a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies.

Inspyr Therapeutics & Lewis and Clark Pharmaceuticals Complete Merger
https://drug-dev.com/inspyr-therapeutics-lewis-and-clark-pharmaceuticals-complete-merger/

Lewis and Clark Pharmaceuticals, Inc. (L&C Pharma) is an early stage drug development company focusing on adenosine receptor-based therapies for a wide range of inflammatory, autoimmune, and other underserved chronic diseases. L&C Pharma was founded in 2011 by Robert Thompson, Ph.D., an acknowledged world leader in adenosine chemistry. Dr. Thompson has assembled a team of leading experts in pre-clinical development, toxicology, and adenosine receptor pharmacology, physiology and molecular biology to develop novel compounds for chronic indications.

Inspyr Therapeutics, Inc. develops therapies for cancer using a novel technology platform that combines a powerful therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors. Mipsagargin, its lead drug candidate, has been studied in a Phase 2 clinical trial in patients with Nexavar®-refractory hepatocellular carcinoma (HCC) and has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication. For additional information on Inspyr Therapeutics, visit www.inspyrtx.com.

Patents Assigned to Lewis and Clark Pharmaceuticals, Inc.
https://patents.justia.com/assignee/lewis-and-clark-pharmaceuticals-inc

Mipsagargin latest update as of June 2018 (with other patent info):

https://adisinsight.springer.com/drugs/800030883

https://patents.justia.com/assignee/inspyr-therapeutics-inc

The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.

MIPSAGARGIN- Inspyr’s drug that can potentially cure various cancers-

MUST WATCH videos about Mipsagargin:

Intro into Mipsagargin by Inspyr(formerly Genspera):

NSPX in the News- Mipsagargin Breakthrough Drug- Potential replacement for chemotherapy:

Physicians React to Phase 2 Update on GenSpera’s Mipsagargin in Hepatocellular Carcinoma at ASCO GI:

Meet Lewis and Clark Pharmaceuticals Management team:



Robert Thompson, PhD, Chief Executive Officer

Over 35 years experience in medicinal chemistry
Acknowledged world leader in adenosine chemistry
Inventor on 20 issued patents
Former VP of Medicinal Chemistry at Adenosine Therapeutics, which was acquired by Forest Labs as part of the Clinical Data deal in 2011



Larry Rodman, PhD, DABT, MT(ASCP), Chief Science Officer

Over 23 years experience in toxicology
Board certified by the American Board of Toxicology
Previously Distinguished Scientist at Sanofi-Aventis
Expert on accelerated pre-clinical study regimen



Jeffrey Totten, MBA, Board Member, Strategy & Business Development Advisor

Over 25 years consulting experience in the pharmaceutical industry
President, Totten & Associates, a strategy/M&A advisory firm
Led strategy/M&A projects in a wide range of therapeutic areas
Extensive network of pharma Business Development and Angel investor group contacts

BOARD OF DIRECTORS

Our board includes an excellent blend of scientific, regulatory, operating, and business development expertise.

Robert Thompson, PhD
Founder, Chairman and CEO of Lewis & Clark Pharmaceuticals, Inc

Joel Linden, PhD
Professor of Inflammatory Biology, La Jolla Institute of Allergy and Immunology A leading expert on pharmacology, physiology and molecular biology of adenosine receptors

Thomas Carter, MD Senior Partner of Augusta Emergency Physicians, Inc.
Practices emergency and internal medicine

Edward Williams, MS
Active, experienced angel investor and technology advisor to Teachstone. Was founder and CEO of Blue Ridge Numerics, Inc. which was acquired by Autodesk in 2011

Miette Michie, MS
Experienced operations manager supporting emerging technologies and early stage start-ups. Former COO of Lewis and Clark Pharmaceuticals and Interim CEO at UVA Patent Foundation

Jeff Totten, MBA
A leading expert on pharmacology, physiology and molecular biology of adenosine receptors

Thomas Carter, MD Senior Partner of Augusta Emergency Physicians, Inc.
Practices emergency and internal medicine

Edward Williams, MS
Active, experienced angel investor and technology advisor to Teachstone. Was founder and CEO of Blue Ridge Numerics, Inc. which was acquired by Autodesk in 2011

Miette Michie, MS
Experienced operations manager supporting emerging technologies and early stage start-ups
Former COO of Lewis and Clark Pharmaceuticals and Interim CEO at UVA Patent Foundation

Jeff Totten, MBA
President, Totten & Associates, a strategy/M&A advisory firm
Has deep experience supporting BD efforts of “big”, specialty, and emerging pharma/med device companies

Scientific Advisory Committee

Robert Thompson, PhD, Chairman
Founder and CEO of Lewis & Clark Pharmaceuticals, Inc.
Joel Linden, Ph.D., Board Member Professor of Inflammation Biology, La Jolla Institute of Allergy and Immunology. World-recognized expert in cell biology and pharmacology of adenosine action
Has co-authored over 200 papers and 15 book chapters on the subject
Founder, Adenosine Therapeutics – was acquired by Forest Laboratories in 2011

Jeff Leighton, Ph.D., Scientific Advisory Committee Member
Pioneer in the development of orally active subtype-selective adenosine antagonistsFormer Burroughs Wellcome scientist

Ralph Stevenson, Ph.D., Scientific Advisory Committee Member
Former SVP of Research at Clinical Data/Adenosine Therapeutics, and Senior Director of Cardiovascular, Endocrine and Metabolic Disease Research at Pfizer

Robert Figler, Ph.D., Scientific Advisory Committee Member
Assistant Professor of Molecular Physiology and Biological Physics at UVA Former Director of Pharmacology at Clinical Data/Adenosine Therapeutics

Thomas Carter, M.D., Board Member
Senior Partner of Augusta Emergency Physicians, Inc.
Specialties in internal and emergency medicine, and treating infections and trauma

NEWS with potential 12 Million Licensing deal with Ridgeway Therapeutics
https://markets.businessinsider.com/news/stocks/inspyr-to-license-oncology-related-compounds-to-ridgeway-therapeutics-inc-1027539438

Reporting Status:

U.S. Reporting: SEC Reporting
Audited Financials

150,000,000 shares authorized 11,383,983 common shares issued and outstanding.

Inspyr Therapeutics Inc.
Lewis & Clark Pharmaceuticals Inc.
http://www.lncpharma.com/
Phone: [phone]
2511 N. Loop 1604 W.
Ste. 204
San Antonio, TX 78258
USA